Biomarker Study of Acamprosate in Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 1/24/2018 |
| Start Date: | June 2008 |
| End Date: | February 2012 |
NMDA receptors are brain receptors that are stimulated by glutamate. Poorly functioning NMDA
receptors are thought to be involved in the pathology of schizophrenia. This hypothesis is
based on the observation that PCP, which blocks the NMDA receptor, produces symptoms and
cognitive impairments similar to schizophrenia. Efforts to enhance the function of the NMDA
receptor with glycine and D-cycloserine have met with limited success. An alternative
approach would be to use the drug acamprosate.
Acamprosate, FDA-approved for maintenance of sobriety after detoxification from alcohol,
seems to act through modulation of the NMDA receptor. In the lab, acamprosate has been noted
to act as an antagonist when the NMDA receptors are maximally stimulated but as an agonist
when NMDA receptor stimulation is minimal. This "smart drug" action makes acamprosate
appealing for use in schizophrenia. If acamprosate works as a smart drug in patients, then we
would predict that it would enhance the function of NMDA receptors in schizophrenia and
improve cognition and the symptoms of the illness. Additionally, acamprosate seems to
modulate the NMDA receptor in novel ways distinct from glycine and D-cycloserine.
We will also see if the response to acamprosate differs based on whether participants do or
do not have a past history of alcohol use disorders.
receptors are thought to be involved in the pathology of schizophrenia. This hypothesis is
based on the observation that PCP, which blocks the NMDA receptor, produces symptoms and
cognitive impairments similar to schizophrenia. Efforts to enhance the function of the NMDA
receptor with glycine and D-cycloserine have met with limited success. An alternative
approach would be to use the drug acamprosate.
Acamprosate, FDA-approved for maintenance of sobriety after detoxification from alcohol,
seems to act through modulation of the NMDA receptor. In the lab, acamprosate has been noted
to act as an antagonist when the NMDA receptors are maximally stimulated but as an agonist
when NMDA receptor stimulation is minimal. This "smart drug" action makes acamprosate
appealing for use in schizophrenia. If acamprosate works as a smart drug in patients, then we
would predict that it would enhance the function of NMDA receptors in schizophrenia and
improve cognition and the symptoms of the illness. Additionally, acamprosate seems to
modulate the NMDA receptor in novel ways distinct from glycine and D-cycloserine.
We will also see if the response to acamprosate differs based on whether participants do or
do not have a past history of alcohol use disorders.
We propose to measure the response of symptoms and cognition in people schizophrenia given
acamprosate or placebo. We hypothesize that symptoms and cognition will improve following two
weeks of acamprosate. We will also use proton magnetic resonance spectroscopy (MRS) to
examine the effect of acamprosate on glutamate & glutamine (Glu&Gln) brain levels in people
with schizophrenia. We hypothesize that Glu&Gln concentrations in people with chronic
schizophrenia will increase following two weeks of treatment with acamprosate.
The proposed study will consist of 50 individuals with chronic schizophrenia/schizoaffective
disorder, 18-55 years old, from in/outpatient programs at the Maryland Psychiatric Research
Center (MPRC). The dose of acamprosate will follow manufacturer recommendations with two
333mg tablets given three times per day. MRS will be acquired from areas involved in
schizophrenia [dorsolateral-prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC)] at
baseline and week two. Symptom ratings and cognitive testing will occur at baseline and be
repeated at week two.
acamprosate or placebo. We hypothesize that symptoms and cognition will improve following two
weeks of acamprosate. We will also use proton magnetic resonance spectroscopy (MRS) to
examine the effect of acamprosate on glutamate & glutamine (Glu&Gln) brain levels in people
with schizophrenia. We hypothesize that Glu&Gln concentrations in people with chronic
schizophrenia will increase following two weeks of treatment with acamprosate.
The proposed study will consist of 50 individuals with chronic schizophrenia/schizoaffective
disorder, 18-55 years old, from in/outpatient programs at the Maryland Psychiatric Research
Center (MPRC). The dose of acamprosate will follow manufacturer recommendations with two
333mg tablets given three times per day. MRS will be acquired from areas involved in
schizophrenia [dorsolateral-prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC)] at
baseline and week two. Symptom ratings and cognitive testing will occur at baseline and be
repeated at week two.
Inclusion Criteria:
- DSM-IV diagnosis of schizophrenia/schizoaffective disorder
- Age 18-55 years
- Male or female
- Any Race/ethnicity
- Participants will be analyzed separately depending on whether they do or do not have a
history of an alcohol use disorder
Exclusion Criteria:
- Pregnant/nursing females or females not using adequate birth control
- Documented history of mental retardation/severe neurological disorder/head injury with
loss of consciousness
- DSM-IV diagnosis of substance dependence in previous six months/abuse in the previous
three months (except nicotine)
- Serious suicidal risk in the previous six months
- History of renal failure/creatinine clearance of less than 50mL/min
- Current treatment with clozapine
- Contraindication to MRI scanning.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials